Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.
D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006027:Glycosides / Q000627:therapeutic use / Q000633:toxicity; D000882:Haplorhini; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007165:Immunosuppression Therapy; D007783:Lactones / Q000627:therapeutic use; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011033:Podophyllin / Q000633:toxicity; D011035:Podophyllum / Q000627:therapeutic use*; D051381:Rats; D013876:Thiophenes / Q000627:therapeutic use / Q000633:toxicity
D000970:Antineoplastic Agents; D006027:Glycosides; D007783:Lactones; D013876:Thiophenes; D011033:Podophyllin